News
Are These Healthcare Stocks Top Takeover Targets?
Following Gilead Sciences' (NASDAQ: GILD) decision to buy Kite Pharma (NASDAQ: KITE) for $11.9 billion in cash, we couldn't help but wonder what other healthcare stocks could be takeover targets,....
Why Clovis Oncology Fell 7.1% in August
Shares of Clovis Oncology (NASDAQ: CLVS), a commercial-stage biotech focused on cancer, fell more than 7% in August, according to data from S&P Global Market Intelligence. The decline was owed....
Are You Buying Gilead Sciences, Inc. for the Wrong Reason?
Gilead Sciences (NASDAQ: GILD) is up about 12% over the last week or so since Novartis (NYSE: NVS) got its chimeric antigen receptor T-cell (CAR-T) therapy Kymriah approved by the FDA.That's just....
Quantum Genomics to Present at Rodman and Renshaw 19th Annual Global Investment Conference
Paris & New York, September 7, 2017
Quantum Genomics (Euronext Growth − FR001164897 − ALQGC; OTCQX: QNNTF), a biopharmaceutical company with the mission of developing new therapies for....
QUANTUM GENOMICS : Présentation de Quantum Genomics à la conférence Rodman et Renshaw 2017
Paris, le 7 septembre 2017
Quantum Genomics (Euronext Growth − FR0011648971 − ALQGC), société biopharmaceutique spécialisée dans le développement de nouvelles thérapies pour des besoins....
BOIRON : Résultats semestriels 2017
(Données ayant fait l'objet d'une revue limitée par les commissaires aux comptes)
Le Conseil d'Administration de BOIRON, réuni le 7 septembre 2017, a établi les comptes sociaux et les comptes....
BOIRON : 2017 half-year results
(Data have been the subject to a limited review by the statutory auditors)
The Board of Directors of BOIRON, at its meeting of September 7, 2017, made up the half-year statutory and....
Here's Why Shire PLC Stock Fell 10% in August
Shares of Shire PLC (NASDAQ: SHPG), a biopharmaceutical company that focuses on treatments for rare diseases, fell 9.94% in August, according to data from S&P Global Market Intelligence.....
Here's Why Alnylam Pharmaceuticals, Inc. Is Slipping Today
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) a clinical-stage biotech developing RNA-based therapies to treat rare diseases, announced an immediate halt to all studies with one of the....
Here's Why Cara Therapeutics Rose 9.6% in August
Cara Therapeutics (NASDAQ: CARA), a clinical-stage biotech focused on drugs that relieve pain, rose by nearly 10% during August, according to data from S&P Global Market Intelligence. The jump....
5 Things You'll Want to Know From Celgene Corporation's Latest Presentation
It's been a busy week for biotech and healthcare conferences. Drugmakers big and small have been making the rounds, answering questions about their current status and future prospects. Celgene....
5 Key Things You Should Watch With Jazz Pharmaceuticals
It's been a great year for Jazz Pharmaceuticals (NASDAQ: JAZZ) shareholders so far. The biotech stock is up more than 35% year to date. However, most of those gains were made in the first....
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
Last week, Gilead Sciences (NASDAQ: GILD) generated plenty of buzz with the announcement of its planned acquisition of Kite Pharma (NASDAQ: KITE). On Wednesday, several of the company's top....
Evotec: Gute News zum Handelsstart
Der Wirkstoffhersteller Evotec meldet heute vorbörslich den Abschluss einer neuen Forschungs-Kooperation. Zusammen mit ABIVAX soll am französischen Standort im Bereich „Behandlung von schweren....
Here's Why Spark Therapeutics Inc. Surged 23.5% in August
Shares of Spark Therapeutics Inc. (NASDAQ: ONCE), a clinical-stage biotech developing gene therapies, rose 23.5% in August, according to data from S&P Global Market Intelligence. The company....
Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, soared 40% in August, according to data from S&P Global Market Intelligence. A generous....
Why Kite Pharma Soared 64.8% in August
Shares of Kite Pharma (NASDAQ: KITE), a clinical-stage biotech focused on chimeric antigen receptor T-cell (CAR-T therapy), skyrocketed 65% in August, according to data from S&P Global Market....
Here's Why Voyager Therapeutics Gained as Much as 24.9% Today
Shares of clinical-stage biopharma Voyager Therapeutics (NASDAQ: VYGR) popped nearly 25% today after the company announced positive results for a phase 1b trial investigating the potential of its....
Why Sarepta Therapeutics Stock Is Rising Today
Shares of mid-cap biotech Sarepta Therapeutics (NASDAQ: SRPT) marched almost 11% higher Wednesday morning on elevated volume. The stock's rally was catalyzed by news of encouraging results from an....
Here's Why Novo Nordisk A/S Gained 12% in August
Shares of Danish pharma giant Novo Nordisk A/S (NYSE: NVO) rose 11.7% in August, according to data from S&P Global Market Intelligence. Investors were relieved to see that the sales stall the....
Upcoming Data Releases Fueled Strong Gains in These 2 Marijuana Stocks Last Week
Though speculators' eyes may be on bitcoin and other cryptocurrencies at the moment, arguably no group of stock-based equities has been stronger over the trailing year than marijuana stocks. If we....
Could These 2 Biotech Stocks Really Double Your Money?
Investment-bank analysts have been slapping lofty price targets on small-cap biotech stocks recently. More than a few targets I've seen recently suggest you could easily double your money or....
7 Medical Conditions That Will Be Lining Big Pharma's Pockets by 2020
Image source: Getty Images.Imagine a stack of dollar bills reaching from the ground to more than 95,000 miles into the sky -- nearly four-tenths of the way to the moon. That stack would total $1.4....
What's Behind Mallinckrodt's 12.2% Tumble Today
Growing concern that generic alternatives to one of its best-selling drugs could threaten future sales and that an investigation into the marketing of opioid pain medication could create headwinds....
Why Exact Sciences Shares Rallied 10.2% in August
After the company reported better-than-expected top- and bottom-line second-quarter results in late July and updated investors on its strategy at Cannacord's 37th annual growth conference on Aug.....